Surgery PartnersNASDAQ: SGRY

Surgery Partners (SGRY) came out with quarterly earnings of $0.21 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.28 per share a year ago.

Investors interested in stocks from the Medical Services sector have probably already heard of Surgery Partners (SGRY) and Medpace (MEDP). But which of these two companies is the best option for those looking for undervalued stocks?

Surgery Partners, Inc. (NASDAQ: SGRY) will announce its first quarter 2024 results on Tuesday, May 7, 2024, before the market opens, followed by a conference call at 8:30 a.m. (Eastern Time).

Surgery Partners (SGRY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The mean of analysts' price targets for Surgery Partners (SGRY) points to a 39% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

While the top- and bottom-line numbers for Surgery Partners (SGRY) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Surgery Partners (SGRY) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.27 per share a year ago.

Get a deeper insight into the potential performance of Surgery Partners (SGRY) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Surgery Partners (SGRY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.